Our research is approved by the Institutional Review Board of the Royan Institute Research Center and the Royan Ethics Committee consistent with Helsinki Declaration with the approval ID of IR.ACECR.ROYAN.REC.1398.213. Anonymity and confidentiality of data were respected.

Dataset studied in this article is collected from Royan Institute, a public none-profitable organization, affiliated to the academic center for education, culture and research (ACECR) in Iran. It includes the features describing the patients having been treated by IUI method in the Infertility clinic at Royan Institute between January 2011 and September 2015.

In this retrospective study, a completed episode is defined as a sequence of treatment cycles resulting in positive clinical pregnancy or when the treatment with IUI is stopped. The inclusion criteria for the couples to be treated under IUI cycles were male factor, ovulatory disorders such as PCOS, hypothalamic amenorrhea, diminished ovarian reserve, combined causes, and unexplained subfertility. The couples' duration of infertility was at least 1 year. Male infertility was defined as the semen quality parameters lower than the standards determined by WHO including sperm concentration lower than 15 million/ejaculate, semen volume lower than 1.5 mL, and total motility lower than 40% [22]. The male partners with donor sperms, Varicocele, and semen samples with total motile sperm count lower than 1 × 106 were excluded from being candidates for IUI treatment. Additionally, patients with anatomical and metabolic abnormalities, severe endometriosis and/or systemic diseases were excluded from our study.

11,255 IUI cycles related to 8,360 couples are considered in which the women age ranges from 16 to 47 with the average age of 29. This dataset contains 1,622 positive outcomes and 9,633 negative ones. Therefore, the overall pregnancy rate is 14.41% per completed cycle and 19.4% per couple. Each couple is treated for 1.31 ± 0.59 (mean ± Standard Deviation) IUI cycles which ranges from 1 to 7 cycle.

The features describe the couples' demographic characteristics, historical data about their diseases, the clinical diagnosis, the treatment plans and the prescribed drugs to the couples, male semen quality, laboratory tests and the clinical pregnancy outcome. The considered demographic features include age, body mass index (BMI), education level, consanguinity with spouse and some other features. The information about the history of the patients' subfertility consists of the duration and type of infertility, length of marriage and so on.

The types of feature values are numerical, binary, nominal and binominal types for 86, 152, 51 and 7 features, respectively. More details about the features is shown in Appendix 1.

In the collected dataset, the majority of couples (almost 72%) have been treated for one cycle, 22% of couples have underwent two cycles, 5% of couples have been treated for three cycles, and less than 1% have been treated more than three cycles. The maximum number of cycles for treating a couple is seven. Figure 2 depicts the distributions of positive and negative clinical pregnancy rates for patients per treatment cycle.

The ratio of positive and negative clinical pregnancy per treatment cycle

As illustrated by Fig. 2, 63% of the couples belonging to the positive class (positive clinical pregnancy after completing the cycle) have been pregnant after the first treatment cycle. 26% of data records in the positive class have received positive outcome after the second cycle. Moreover, 74% of the couples in the negative class have been considered after the first cycle.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.